Innovative Therapies to Treat and Cure HDV and Other Serious Diseases



June 2022

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our anticipated significant milestones in 2022; the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations; the likelihood of submitting and obtaining an Emergency Use Authorization from the FDA for peginterferon lambda for COVID-19; expectations regarding the timing and availability of topline data from our Phase 3 D-LIVR study in HDV; the ability to fully enroll the Phase 3 LIMT-2 study; commencing a Phase 3 study of avexitide in congenital hyperinsulinism; the successful commercialization of Zokinvy in jurisdictions outside of the U.S., including the EU; our capability to provide sufficient quantities of any of our product candidates, including peginterferon lambda, to meet anticipated full-scale commercial demands; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements and public dillog and place flings with the SEC. The forward-looking statements ontained in this preserent on Form 10-Q for the quarter ended March 31, 2022 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based o





Advancing Pipeline for HDV and Other Serious Diseases

Indication	Product Candidate	Phase 2	Phase 3	Marketed
Hepatitis Delta Virus	Lonafarnib			
	Peginterferon Lambda			
COVID-19	Peginterferon Lambda			
Congenital Hyperinsulinism				
Post-Bariatric Hypoglycemia	Avexitide			
Progeria	(lonafarnib) capsules 50 mg/75 mg			



HDV: A Deadly Global Disease

TREATMENTS DESPERATELY NEEDED

>12M Patients globally

50%

of patients are cirrhotic at the time of diagnosis

Eiger HDV Platform

FIRST IN CLASS TREATMENTS IN DEVELOPMENT FOR HDV





HDV: Always a Co-infection with HBV

HDV REQUIRES HBsAg TO COMPLETE VIRUS ASSEMBLY





HDV: Most Severe Form of Viral Hepatitis

50% OF PATIENTS CIRRHOTIC AT DIAGNOSIS









Different Mechanisms of Action to Treat HDV





Eiger Developing Complementary Treatments for HDV



Eiger HDV Platform in Phase 3

FIRST IN CLASS TREATMENTS IN DEVELOPMENT FOR HDV

Lonafarnib

- Only oral agent in development
- 2,000+ patients dosed in oncology
- 450+ patients dosed in HDV
- 100+ patients dosed in Progeria
- Orphan Designation in U.S. and EU
- FDA Breakthrough Therapy Designation
- Patent protection through late-2030s

Peginterferon Lambda

- Well-tolerated interferon
- 3,000+ patients dosed in HCV / HBV
- 50+ patients dosed in HDV
- 1,000+ patients dosed in COVID-19
- Orphan Designation in U.S. and EU
- FDA Breakthrough Therapy Designation
- 12 years biologics exclusivity

What Does a Win Look Like for HDV Patients?

CONSISTENT WITH FDA GUIDANCE ON DEVELOPMENT OF TREATMENTS FOR HDV*

- Reduction in HDV Viral Load
 - Improvement in Liver Inflammation (ALT)

- Slows Disease Progression
- Improves Liver Histology
- Improves Survival





Lonafarnib Phase 2 Program: 129 HDV Patients Dosed

TWO LONAFARNIB-BASED REGIMENS IDENTIFIED FOR REGISTRATION









MULTIPLE PATHWAYS TO APPROVAL



* biopsy

All patients will be maintained on background HBV nucleoside therapy. Superiority over PEG IFN-alfa-2a not required.









Topline Data Planned by End of 2022







Peginterferon Lambda for HDV

A WELL TOLERATED INTERFERON







Phase 2 Peginterferon Lambda Study Results

36% DURABLE VIROLOGIC RESPONSE (DVR) WITH PEGINTERFERON LAMBDA







LVMT-2 Peginterferon Lambda Phase 3 Study of HDV ACTIVATING SITES AND ENROLLING PATIENTS



*Primary Endpoint: DVR (Arm 1) versus HDV RNA BLQ After 12 Weeks No TRx (Arm 2)

DVR (Durable Virologic Response) = Below the Limit of Quantification (BLQ) at 24 Weeks Post-Treatment





L ↓ MT − 2 Phase 3 Global Study OVERLAP WITH D-LIVR SITES; POISED FOR EFFICIENT ENROLLMENT

Enrolling BELGIUM Patients GERMANY MOLDOVA RANCE ROMANIA GEORGIA ITALY BULGARIA SPAIN TURKEY **UNITED STATES** N=150 12 50 ISRAEL-COUNTRIES SITES



Strong Momentum Across Hepatitis Delta Virus Platform

FIRST IN CLASS TREATMENTS IN DEVELOPMENT FOR HDV





\$1B+ HDV Market Opportunity

ONLY 3% MARKET PENETRATION REQUIRED





Concentrated U.S. Prescriber Base: Targeted Field Promotion

70% OF U.S. HBV RX WRITTEN BY 10% OF TOTAL PRESCRIBERS





Commercial Launch Strategy

>\$1B COMMERCIAL OPPORTUNITY IN U.S., EUROPE, AND CHINA





Foundational Therapies to Treat and Cure HDV





COVID-19: An Evolving Pandemic

MORE TREATMENTS NEEDED

~530M

Cases to date globally

~6.3M Deaths to date globally



Press Release March 17, 2022

Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 *TOGETHER* Study

- Second largest study to date in COVID-19 outpatients (N>1,900)
- Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint
- 60% reduced risk of COVID-19-related death
- Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron
- Eiger plans to submit data to FDA for Emergency Use Authorization (EUA)



together • COVID-19 Phase 3 Study SECOND LARGEST TREATMENT STUDY IN COVID-19

- Multi-center, investigator-sponsored, randomized, placebo-controlled Phase 3 study in Brazil (12 sites)
- Single injection of Peginterferon Lambda vs. Placebo
- Randomized within 7 days of symptom onset and positive SARS-CoV-2 test
- Enrolled >1,900 high-risk, non-hospitalized, 84% vaccinated patients from Jul 2021 Feb 2022
- High-risk criteria defined by patients having at least one of the following criteria, including but not limited to:
 > age 50, diabetes, hypertension, CV disease, lung disease, kidney disease, obesity, etc.
- Primary endpoint is reduction of COVID-19–related hospitalizations or emergency room visits through Day 28
- Key secondary endpoint is reduction of COVID-19–related hospitalizations or deaths through Day 28



together•COVID-19 Phase 3 Study

ROBUST, LARGE SCALE STUDY REPRESENTATIVE OF CURRENT, REAL-WORLD COVID-19 POPULATION

Risk	# Days of Symptoms Before Treatment	Risk Reduction (95% BCI)	Probability of Superiority*
Hospitalizations or ER visits	≤ 7 days	50% (23 - 69%)	99.9%
	≤ 3 days	67% (19 - 79%)	99.6%
Hospitalizations or Deaths	≤ 7 days	39% (1 – 64%)	97.7%
	≤ 3 days	60% (17 – 82%)	99.4%

- 60% reduction in hospitalizations or death with early treatment
- 1 death in Lambda group; 4 deaths in Placebo group
- Primary endpoint achieved in a pan-variant population
- Potential for efficacy to new arising variants
- Incidence of AEs indistinguishable between lambda and placebo



together • COVID-19 Phase 3 Study

PRELIMINARY ANALYSIS DEMONSTRATES LAMBDA IS ACTIVE AGAINST MULTIPLE VARIANTS

Time Period	Dominant Variant	Lambda N (# events)	Placebo N (# events)
Jun 21 to Feb 22	Full Study	916 (25)	1001 (57)
Dec 21 to Feb 22	Omicron	425 (2)	500 (18)
Aug 21 to Dec 21	Delta	358 (12)	363 (23)
Jun 21 to Aug 21	Gamma	128 (11)	138 (16)



- Preliminary analysis of treatment response against dominant variants: Gamma, Delta, and Omicron
- Jun 2021 to Aug 2021 (Gamma predominant)
 - 25% risk reduction during this earliest period
- Aug 2021 to Dec 2021 (Delta predominant)
 - 46% risk reduction
- Dec 2021 to Feb 2022 (Omicron predominant)
 - Highest risk reduction of 83%



Peginterferon Lambda for COVID-19

POTENTIAL "ONE AND DONE" TREATMENT FOR NEWLY DIAGNOSED COVID-19 OUTPATIENTS





Peginterferon Lambda for COVID-19

POTENTIAL AS A CONVENIENT, OUTPATIENT THERAPY FOR NEWLY DIAGNOSED PATIENTS

- Actively engaged with FDA and preparing EUA submission
- *TOGETHER* team completing analyses for EUA application (>1,900 patients)
- Plan to share full data analyses and host investor call at time of EUA application





Rare Diseases: Urgent Medical Needs



- FDA Approved for Progeria
- Positive CHMP Opinion on May 20

Avexitide

Congenital Hyperinsulinism

Congenital Hyperinsulinism (HI)

AN ULTRA-RARE, LIFE-THREATENING DISORDER AFFECTING NEONATES AND CHILDREN

- Most frequent cause of persistent hypoglycemia in neonates and children
- Occurs in 1:25,000 to 1:50,000 live births
- Requires high glucose infusion rates to maintain euglycemia
- Near-total pancreatectomy is often indicated and leads to T1DM
- Results in irreversible brain damage in up to 50% of patients
- No approved therapy





Avexitide: First-in-Class GLP-1 Antagonist

TARGETS UNDERLYING PHYSIOLOGY OF HI TO PREVENT HYPERINSULINEMIC HYPOGLYCEMIA



34

- **↓** basal GLP-1r signaling
- cAMP-mediated insulin release
- Prevents dysregulated insulin secretion
- Prevents fasting and protein-induced hypoglycemia



Avexitide: First-in-Class GLP-1 Antagonist

TARGETED THERAPY FOR CONGENITAL HYPERINSULINISM

- Novel liquid formulation developed for subcutaneous delivery
- FDA Breakthrough Therapy designation
- FDA Rare Pediatric Disease designation
- Patent protection will provide market exclusivity through at least 2039

Vant Phase 3 **AVANT** Program Initiating in 2022



Advancing Pipeline for HDV and Other Serious Diseases

Indication	Product Candidate	Phase 2	Phase 3	Marketed
Hepatitis Delta Virus	Lonafarnib	D-LIVF	2	
	Peginterferon Lambda	<u>LvMT-2</u>		
COVID-19	Peginterferon Lambda	together• COVID-19		
Congenital Hyperinsulinism	Averitide	Avant		
Post-Bariatric Hypoglycemia	Avexitide			
Progeria	(lonafarnib) capsules 50 mg/75 mg			



A Pivotal Moment for Eiger

Potential for "One-and-Done" Therapy for COVID-19

- Actively engaging with FDA
- Preparing EUA application

Zokinvy Progeria EU Launch Expected in 2022

Delivering Needed Wins for HDV Patients

- Phase 3 *D*-*LIVR* Lonafarnib data by end of 2022
- Phase 3 LIMT-2 Lambda study enrolling

Advancing Avexitide for Congenital Hyperinsulinism

• Phase 3 *AVANT* program initiating in 2022

Preparing for Future Growth

• Expanding our leadership team

Strong Balance Sheet

• Planned Operations Funded through 2024